{
    "clinical_study": {
        "@rank": "57050", 
        "arm_group": [
            {
                "arm_group_label": "Placebo IV", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants with psoriasis will receive a single dose of placebo matching LY3074828 intravenously (IV)"
            }, 
            {
                "arm_group_label": "LY3074828 IV", 
                "arm_group_type": "Experimental", 
                "description": "Participants with psoriasis will receive a single escalating dose of LY3074828 starting at 5 mg, IV"
            }, 
            {
                "arm_group_label": "LY3074828 SQ", 
                "arm_group_type": "Experimental", 
                "description": "Participants with psoriasis will receive a single dose of LY3074828 subcutaneously (SQ).  Dose to be determined based upon pharmacokinetic/pharmacodynamic (PK/PD) data."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate the safety of the study drug known as\n      LY3074828 in participants with psoriasis.  The study will investigate how the body processes\n      the study drug and how the drug affects the body.  The study will last about 3 months for\n      each participant."
        }, 
        "brief_title": "A Study of LY3074828 in Participants With Psoriasis", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic plaque psoriasis based on an investigator confirmed diagnosis of chronic\n             psoriasis vulgaris for at least 6 months prior to baseline\n\n          -  Plaque psoriasis involving >2% body surface area (BSA) in affected skin other than\n             the face and scalp at screening and baseline\n\n          -  Are willing and able to undergo baseline and posttreatment skin lesion biopsy\n\n          -  Are willing and able to washout topicals for at least 14 days before baseline on the\n             2 target lesions\n\n          -  Have adequate organ function including absolute neutrophil count >1.5\n             cells/microliter (uL), hemoglobin level >10 grams/deciliter (g/dL), lymphocyte count\n             >500 cells/uL, total white blood cell count >3.0 cells/uL, bilirubin level <1.5 times\n             the upper limit of normal (ULN) and alkaline phosphatase, alanine transaminase and\n             aspartate transaminase <1.5 times ULN\n\n        Exclusion Criteria:\n\n          -  Have had a clinically significant flare of psoriasis during the 12 weeks before\n             randomization\n\n          -  Have a history of drug-induced psoriasis or parapsoriasis\n\n          -  Within 28 days prior to baseline:  have received systemic nonbiologic psoriasis\n             therapy (including, but not limited to, oral psoralen plus ultraviolet A light\n             therapy (PUVA); cyclosporine; corticosteroids; methotrexate; oral retinoids;\n             mycophenolate mofetil; thioguanine; hydroxyurea; sirolimus; azathioprine; fumaric\n             acid derivatives; or 1, 25 dihydroxy vitamin D3 and analogues or phototherapy\n             (including either oral and topical PUVA light therapy, ultraviolet B or\n             self-treatment with tanning beds or therapeutic sunbathing)\n\n          -  Within 14 days prior to baseline: have received topical psoriasis treatment\n             (including, but not limited to, corticosteroids, anthralin, calcipotriene, topical\n             vitamin D derivatives, retinoids, tazarotene, emollients and other nonprescription\n             topical products containing urea, >3% salicylic acid, alpha- or beta-hydroxyl acids,\n             or medicated shampoos [for example those that contain >3% salicylic acid,\n             corticosteroids, coal tar, or vitamin D3 analogues])\n\n          -  Have recurrent or persistent uncontrolled Stage 1 hypertension (systolic blood\n             pressure of 140-159 millimeters of mercury [mmHg] or diastolic blood pressure of\n             90-99 mmHg) or greater according to the National Cancer Institute (NCI) Common\n             Terminology Criteria for Adverse Events (CTCAS 4.0)\n\n          -  Evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV\n             antibodies\n\n          -  Evidence of or test positive for hepatitis C virus (HCV)\n\n          -  Evidence of hepatitis B and/or positive hepatitis B surface antigen or are positive\n             for hepatitis B core antibody and negative for hepatitis B surface antibody\n\n          -  Have had clinically significant symptomatic herpes zoster within 3 months of\n             screening\n\n          -  Show evidence of active or latent tuberculosis\n\n          -  Have received live vaccine(s) (included attenuated live vaccines) within 1 month of\n             screening or intend to during the study\n\n          -  Have received treatment with biologic therapies for psoriasis (such as monoclonal\n             antibodies, including marketed or investigational biologic therapy).  Prior or\n             current use of biologics for indications other than psoriasis may be allowed with\n             sponsor approval\n\n          -  Have had lymphoma, leukemia, or any malignancy within the past 5 years, except for\n             basal cell or squamous epithelial carcinomas of the skin that have been resected with\n             no evidence of metastatic disease for 3 years and cervical carcinoma in situ, with no\n             evidence of recurrence within 5 years prior to baseline\n\n          -  Have any other skin conditions (excluding psoriasis) that would affect interpretation\n             of the results (including, but not limited to, scleroderma eczema or cutaneous\n             manifestations of other autoimmune disease - such as systemic lupus erythematosus)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947933", 
            "org_study_id": "15039", 
            "secondary_id": "I6T-MC-AMAA"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY3074828 IV", 
                "description": "Administered IV", 
                "intervention_name": "LY3074828 - IV", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "LY3074828 SQ", 
                "description": "Administered SQ", 
                "intervention_name": "LY3074828 - SQ", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo IV", 
                "description": "Administered IV", 
                "intervention_name": "Placebo - IV", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 30, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Waterloo", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N2J 1C4"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2K4L5"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I, Randomized, Placebo-Controlled Study of LY3074828, an Anti-IL-23 Humanized Antibody, in Subjects With Psoriasis", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline through 12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947933"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3074828", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 12 Weeks"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3074828", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 12 Weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}